# Study of Tecovirimat for Human Monkeypox Virus (STOMP)

> **NIH NIH UM1** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2022 · $5,882,075

## Abstract

PROJECT SUMMARY
The AIDS Clinical Trials Group (ACTG) has been at the forefront of clinical research to advance HIV
therapeutics and improve the health of patients living with HIV/AIDS for 25 years. Rigorous scientific research
conducted by the ACTG has laid the cornerstones for current HIV treatment guidelines. In this application for
the competitive renewal of the ACTG Network Laboratory Center, we propose a transformative laboratory
research agenda that draws on an international consortium of prominent clinical and laboratory investigators in
collaboration with a world-class Statistical and Data Management Center to conduct leading edge laboratory
research, testing, assay development and laboratory training for the support of innovative interventional clinical
trials. The component ACTG Network Laboratory Center will improve scientific knowledge and technical
capability by providing state-of-the-art laboratory support in the four NIH/DAIDS priority areas of strategies to
cure HIV; improve the diagnosis and treatment of tuberculosis; identify strategies to cure infectious viral
hepatitis; improve the treatment and prevention of non-infectious co-morbidities associated with HIV infection
and evaluate novel interventions targeting HIV infection. In addition, the Laboratory Center will provide
laboratory support for therapeutic studies of oral manifestations of HIV/AIDS and virally mediated cancers. The
continued expansion of an effective, quality-assured laboratory program at domestic and international sites for
protocol safety measures, state-of-the-art molecular assays for virology and mycobacteriology; immunology
and biomarkers; pharmacology; genomics; and oral pathogens associated with HIV-1 infection, will provide the
essential framework for advancing the scientific agenda of the ACTG Network. The Laboratory Center will
continue to provide oversight of established specimen and human DNA repositories for the ACTG Network,
harmonize specific laboratory testing and standardized operating procedures with other Networks where
feasible and continue to support the laboratory training of technologists and investigators domestically and
internationally.

## Key facts

- **NIH application ID:** 10689623
- **Project number:** 3UM1AI106701-09S1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** Grace M Aldrovandi
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $5,882,075
- **Award type:** 3
- **Project period:** 2022-09-13 → 2023-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10689623

## Citation

> US National Institutes of Health, RePORTER application 10689623, Study of Tecovirimat for Human Monkeypox Virus (STOMP) (3UM1AI106701-09S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10689623. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*